Researchers from Hokkaido University and Toppan Have Developed an Exosome-Based Method to Detect Build-Up of Amyloid Beta (AB) in the Brain, a Characteristic of Alzheimer’s Disease; Test Detects Exosome-Bound AB Surface Biomarkers in Blood Samples

Artistic Rendering of Exosomes

Alzheimer’s disease is a neurodegenerative disease, characterized by a gradual loss of neurons and synapses in the brain. One of the primary causes of Alzheimer’s disease is the accumulation of amyloid β (Aβ) in the brain, where it forms plaques. Alzheimer’s disease is mostly seen in individuals over 65 years of age, and cannot currently be stopped or reversed. Thus, Alzheimer’s disease is a major concern for nations with aging populations, such as Japan. A team of scientists from Hokkaido University and Toppan, led by Specially Appointed Associate Professor Kohei Yuyama, PhD, at the Faculty of Advanced Life Science, Hokkaido University, have developed a biosensing technology that can detect Aβ-binding exosomes in the blood of mice, which increase as Aβ accumulates in the brain. Their research was published on October 3, 2022 in Alzheimer's Research & Therapy. The article is titled “Immuno-Digital Invasive Cleavage Assay for Analyzing Alzheimer’s Amyloid β-Bound Extracellular Vesicles.”

Login Or Register To Read Full Story